Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

Bone Marrow Transplantation volume 43, pages 839–843 (2009)Cite this article

Abstract

Decitabine is a hypomethylating agent with activity in myelodysplastic syndrome (MDS). It is largely unknown whether treatment with this drug before allo-SCT will increase the toxicity of the preparative regimen or otherwise affect the results of the transplant. We report the outcome of 17 patients with MDS with a median age of 55.5 years (range, 36–66 years) who underwent an allo-SCT (12 siblings, 5 unrelated) after prior therapy with decitabine. Preparative regimens consisted of fludarabine in combination with BU (n=8) or melphalan (n=9). The source of stem cells was marrow in four patients and peripheral blood (PB) in 13 patients. Thirteen patients were in CR within 100 days of transplant. With a median follow-up of 12 months (range, 3–35 months), 11 patients are alive; eight in CR and three with progressive disease. Prior therapy with hypomethylating agents did not increase toxicity and may improve the outcome of allogeneic transplant in MDS and should be evaluated in a prospective trial.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Schiffer CA . Clinical issues in the management of patients with myelodysplasia. In: Gerwitz AM, Winter JN, Zuckerman K (eds). Hematology, Am Soc Hematol Educ Program, 2006, pp 205–210.

    Article  Google Scholar 

  2. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440.

    Article  CAS  Google Scholar 

  3. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.

    Article  CAS  Google Scholar 

  4. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.

    Article  CAS  Google Scholar 

  5. Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–2054.

    Article  CAS  Google Scholar 

  6. Issa JP . CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988–993.

    Article  CAS  Google Scholar 

  7. Issa JP . Optimizing therapy with methylation inhibitors in myelodysplastic syndromes:dose, duration, and patient selection. Nat Clin Pract Oncol 2005; 2: 24–29.

    Article  Google Scholar 

  8. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP . Methylation profiling in acute myeloid leukemia. Blood 2001; 97: 2823–2829.

    Article  CAS  Google Scholar 

  9. Pinto A, Zagonel V . 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7: 51–60.

    PubMed  Google Scholar 

  10. Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R . Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 1984; 2: 867–868.

    Article  CAS  Google Scholar 

  11. Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A et al. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989; 4: 28–32.

    PubMed  Google Scholar 

  12. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57.

    Article  CAS  Google Scholar 

  13. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Atein H et al. (eds). World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer (IARC), 2008, 439pp.

    Google Scholar 

  14. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplasia syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–585.

    Article  CAS  Google Scholar 

  15. Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB . Overview of the SEER—medicare health outcomes survey linked dataset. Health Care Financ Rev 2008 Summer; 29: 5–21.

    PubMed  PubMed Central  Google Scholar 

  16. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620–630.

    Article  CAS  Google Scholar 

  17. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidities index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    L De Padua Silva, M de Lima, P Kebriaei, S Giralt & R Champlin

  2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    L De Padua Silva, H Kantarjian, S Faderl, J Davisson, G Garcia-Manero, J-P Issa & F Ravandi

Authors
  1. L De Padua Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M de Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Faderl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Kebriaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Davisson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Garcia-Manero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J-P Issa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Ravandi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M de Lima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Padua Silva, L., de Lima, M., Kantarjian, H. et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43, 839–843 (2009). https://doi.org/10.1038/bmt.2008.400

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.400

Keywords

This article is cited by

Search

Advanced search

Quick links